In biopsy-proven human studies, both circulating levels of fetuin-A and the hepatic expression of fetuin-A were higher in NAFLD patients than in healthy controls regardless of the histological state and BMI class [29], implying that the BMI-oriented concept for NAFLD or MAFLD might need to be reconsidered. Here, AHSG is linked to metabolic dysfunction-associated steatotic liver disease.